Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of chitosan oligosaccharide in preparation of medicaments for preventing and/or treating neurodegenerative diseases

A neurodegenerative and chitosan oligosaccharide technology, applied in the fields of nervous system diseases, neuromuscular system diseases, antipyretics, etc., can solve the problems such as the anti-neurodegenerative disease effect of chitosan oligosaccharide, inflammatory reaction damage, etc. To achieve the effect of improving immunity, lowering blood sugar, and good biocompatibility

Inactive Publication Date: 2013-10-30
DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Under normal physiological conditions, it mainly plays an immune surveillance role, but in some cases, the inflammatory response can also lead to damaging effects
However, there is no research on the anti-neurodegenerative effect of chitosan oligosaccharides

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chitosan oligosaccharide in preparation of medicaments for preventing and/or treating neurodegenerative diseases
  • Application of chitosan oligosaccharide in preparation of medicaments for preventing and/or treating neurodegenerative diseases
  • Application of chitosan oligosaccharide in preparation of medicaments for preventing and/or treating neurodegenerative diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Oligochitosan is administered in the form of an aqueous preparation, and the specific operation of the liquid preparation is as follows: (1) accurately take by weighing 10.0 mg oligochitosan, be dissolved in 10 ml of IMDM medium (V / V) containing 10% fetal bovine serum, The formation of oligochitosan with a final concentration of 1 mg / ml; (2) filter the aforementioned medicinal liquid with a needle filter with a pore size of 0.22 μm to obtain a sterile oligochitosan stock solution; (3) divide the above-mentioned stock solution into After loading, they were stored at -80°C and used in the following examples.

Embodiment 2

[0034] Analysis of iNOS transcriptional repression by oligochitosan on LPS-induced N9 microglia. The main operations are as follows: (1) The experiment is divided into 5 groups, which are normal cell control group (Control), lipopolysaccharide model group (LPS), chitooligosaccharide pre-protection treatment group 1 (50 μg / ml), chitooligosaccharide pre-protection group 1 Protection treatment group 2 (100 μg / ml), chitooligosaccharide pre-protection treatment group 3 (200 μg / ml). (2) The cultured N9 microglial cells were digested with trypsin (0.125%), and then 5×10 4 Inoculate in a 6-well plate at a density of / ml, add 3ml of IMDM culture solution to each well, and store at 37°C, 5% CO 2 cultured in an incubator for 24 h. (3) Take out the 6-well plate, discard the supernatant, add 3ml of fresh IMDM medium to the control and LPS groups, respectively, and add 50, 100 and 200 μg / ml chitosan oligosaccharides to the IMDM culture in the chitosan oligosaccharide pre-protection group ...

Embodiment 3

[0037] Analysis of protein expression inhibition of iNOS by oligochitosan in N9 microglial cells. The main operations are as follows: (1) The experiment is divided into 5 groups, which are normal cell control group (Control), lipopolysaccharide model group (LPS), chitooligosaccharide pre-protection treatment group 1 (50 μg / ml), chitooligosaccharide pre-protection group 1 Protection treatment group 2 (100 μg / ml), chitooligosaccharide pre-protection treatment group 3 (200 μg / ml). (2) The cultured N9 microglial cells were digested with trypsin (0.125%), and then 5×10 4 Inoculate in a 6-well plate at a density of / ml, add 3ml of IMDM culture solution to each well, and store at 37°C, 5% CO 2 cultured in an incubator for 24 h. (3) Take out the 6-well plate, discard the supernatant, add 3ml of fresh IMDM medium to the control and LPS groups, respectively, and add 50, 100 and 200 μg / ml chitosan oligosaccharides to the IMDM culture in the chitosan oligosaccharide pre-protection group...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicament for treating neurodegenerative diseases and particularly relates to an application of chitosan oligosaccharide in preparation of medicaments for preventing and / or treating neurodegenerative diseases, i.e., the chitosan oligosaccharide can be further applied to the medicaments for preventing and / or treating the neurodegenerative diseases. According to the medicament and the application thereof, with lipopolysaccharide (LPS) as an inducing factor and mouse microglia as a research object, a result shows that the chitosan oligosaccharide can remarkably restrict the expression of the activated microglia iNOS (Inducible Nitric Oxide Synthase) in mRNA (Messenger Ribonucleic Acid) and protein level, can restrict the generation of activated microglia NO (Nitric Oxide), can effectively restrict the generation of activated microglia ROS (Reactive Oxygen Species), can effectively restrict the activation of an MAPK (Mitogen Activated Protein Kinase) signal channel caused by LPS, and can effectively restrict the activation of transcription factor NF-kB (Nuclear Factor-Kappa B) and AP-1 (Activator Protein-1).

Description

technical field [0001] The invention belongs to the technical field of medicine, and relates to a medicine for preventing and / or treating diseases related to the activation of microglial cells, specifically the application of chitosan oligosaccharides in the preparation of medicines for preventing the occurrence of neurodegenerative diseases. The chitosan oligosaccharide is used in the preparation of medicine or health food for treating neuron damage caused by inflammatory microglial cells, resulting in neurodegenerative diseases. Background technique [0002] Neurodegenerative disease is a general term for a class of diseases characterized by the gradual loss of neuron structure and function, including neuron death. Alzheimer's disease, also known as senile dementia, is a common neurodegenerative disease characterized by the loss (or degeneration) of nerve cells, β-amyloid deposition and neurofibrillary tangles in the brain . It is a progressive, fatal neurodegenerative d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7016A61K31/702A61K31/722A61P25/00A61P29/00A61P25/28A61P21/00
Inventor 杜昱光魏鹏许青松李昱
Owner DALIAN INST OF CHEM PHYSICS CHINESE ACAD OF SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com